Windtree Therapeutics Inc (WINT)
4.56
+0.50
(+12.32%)
USD |
NASDAQ |
May 15, 16:00
4.56
0.00 (0.00%)
After-Hours: 16:24
Windtree Therapeutics Cash from Financing (Quarterly): 0.521M for Dec. 31, 2023
Cash from Financing (Quarterly) Chart
Historical Cash from Financing (Quarterly) Data
| Date | Value |
|---|---|
| December 31, 2023 | 0.521M |
| September 30, 2023 | -0.233M |
| June 30, 2023 | 10.72M |
| March 31, 2023 | 0.591M |
| December 31, 2022 | 1.116M |
| September 30, 2022 | 1.157M |
| June 30, 2022 | 0.895M |
| March 31, 2022 | -0.089M |
| December 31, 2021 | 2.912M |
| September 30, 2021 | -0.04M |
| June 30, 2021 | -1.119M |
| March 31, 2021 | 27.61M |
| December 31, 2020 | 0.048M |
| September 30, 2020 | -1.137M |
| June 30, 2020 | 21.25M |
| March 31, 2020 | -0.199M |
| December 31, 2019 | 22.74M |
| September 30, 2019 | -0.346M |
| June 30, 2019 | -0.027M |
| March 31, 2019 | -0.598M |
| December 31, 2018 | 30.42M |
| September 30, 2018 | 3.28M |
| June 30, 2018 | 2.541M |
| March 31, 2018 | 2.50M |
| December 31, 2017 | 4.871M |
| Date | Value |
|---|---|
| September 30, 2017 | 2.60M |
| June 30, 2017 | 0.039M |
| March 31, 2017 | 9.786M |
| December 31, 2016 | 0.238M |
| September 30, 2016 | 0.402M |
| June 30, 2016 | 0.069M |
| March 31, 2016 | 0.00 |
| December 31, 2015 | 0.00 |
| September 30, 2015 | 27.74M |
| June 30, 2015 | -0.021M |
| March 31, 2015 | -0.02M |
| December 31, 2014 | -0.021M |
| September 30, 2014 | -0.017M |
| June 30, 2014 | -0.02M |
| March 31, 2014 | 0.435M |
| December 31, 2013 | 75.54M |
| September 30, 2013 | -0.015M |
| June 30, 2013 | 15.09M |
| March 31, 2013 | 9.833M |
| December 31, 2012 | -0.066M |
| September 30, 2012 | -0.018M |
| June 30, 2012 | 0.01M |
| March 31, 2012 | 50.30M |
| December 31, 2011 | 0.32M |
| September 30, 2011 | -0.037M |
Cash From Financing Definition
Cash flow from financing is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall financing activities of the company. A few examples of financing activities include common stock issuance, total dividends paid, and net debt issuance.
Cash from Financing (Quarterly) Range, Past 5 Years
-1.137M
Minimum
Sep 2020
27.61M
Maximum
Mar 2021
4.545M
Average
0.521M
Median
Dec 2023
Cash from Financing (Quarterly) Benchmarks
| Lexicon Pharmaceuticals Inc | 239.38M |
| AIM ImmunoTech Inc | 0.147M |
| Perspective Therapeutics Inc | 0.352M |
| Protalix BioTherapeutics Inc | 0.00 |
| Armata Pharmaceuticals Inc | 34.93M |
Cash from Financing (Quarterly) Related Metrics
| Cash from Operations (Quarterly) | -3.567M |
| Free Cash Flow | -13.45M |
| Free Cash Flow Per Share (Quarterly) | -11.86 |
| Free Cash Flow Yield | -1.37K% |